Preferred Label : CT-P13;

Details


Main resources

You can consult :


http://documents.irevues.inist.fr/handle/2042/58964
10.4267/2042/58964
2016
false
false
false
France
French
journal article
biosimilar pharmaceuticals
CT-P13
inflammatory bowel diseases
biosimilar pharmaceuticals
biosimilar pharmaceuticals
therapeutic equivalency
economics, pharmaceutical
legislation, pharmacy
Substitution of biosimilar product
Infliximab
infliximab
antibodies, monoclonal

---
Nous contacter.
02/05/2025


[Home] [Top]

© Rouen University Hospital. Any partial or total use of this material must mention the source.